elderly lady walks up to a competitor's hamburger stand, looks into her sesame seed roll, and shouts 'Where's the beef? ' The commercial was a huge success and the phrase came into common colloquial usage for challenging the substance of someone's point of view. A senior financial analyst reviewing the commercial aspects of the 'post-genomics revolution' recently asked me: 'SNPsFso where's the beef? ' The product in this case is not hamburgers, but medicines. However, the challenge is the same F is there a practical use for all those single nucleotide polymorphisms (SNPs) based on economic reality? The end point of the biotechnical food chain is not simply elegant science, but discovering new, safe and effective medicines that will address unmet medical needs Fat least that is the rationale stated in numerous grant applications and business plans. Why else would large pharmaceutical companies invest in SNP technology? [1] [2] [3] A recent Science report from an NIHsponsored SNP meeting asked: 'Can SNPs Deliver on Susceptibility Genes?'. 4 Perhaps identifying disease gene associations is not the most practical or important application of SNP mapping technologies. Are SNPs just hype, or are there visible milestones that can measure the business impact over reasonable timelines? To understand a more productive role of SNP mapping, think not about technical advances and susceptibility gene searches, but about the creation of useful medicines in a highly regulated business environment. Just as hamburger chains have changed cultures worldwide, can SNP mapping contribute to making new, safe and effective medicines available to patients faster and with less expense? A new medicine has high medical value, particularly when there is a significant improvement in efficacy and safety over existing treatments. Productivity in the pharmaceutical industry is defined by the development of safer medicines with greater utility, successfully treating more clinical indications, with lower costs and faster timelines. Finding susceptibility genes by SNP mapping is also possible, but only if accompanied by extensive collections of DNA from patients and proper controls, and an accurate clinical database. The immediate impact of SNPs will come from pharmacogenetics, while the longer-term benefits will come from being able to generate genetically associated targets for drug discovery in humans while significantly reducing pipeline attrition and costs.
Some of the larger pharmaceutical companies are excited about SNPs because they believe that both adverse event (AE) and efficacy pharmacogenetics will hit their bottom line and begin to change industry economics well before this decade is over. Pharmacogenetics experiments using SNP map technology are already under way. The timeline can be divided into three time periods: short, medium and long term. Table 1 suggests that disease gene identification including those variants that are amenable to high-throughput screening of targets will impact the practice of medicine more slowly than pharmacogenetics. Thus, increased business productivity over the next few years will be mostly generated through pharmacogenetics, while targets will continue to be identified and screened and leads developed during that time. The first high-density SNP map was constructed in 1997 around the APOE gene and published the next year. 5 The question was simple: Could high-density SNP mapping identify a known disease susceptibility polymorphism (APOE4) against a relatively large (in 1997) 4-Mb background? SNP mapping did indeed accelerate the rediscovery of the APOE4 polymorphism associated with Alzheimer's disease. 6, 7 Then, in 1999, Krugliak predicted that 3-kb distances between SNPs were needed to find genes using SNP mapping. 8 This put a temporary chill on the transition to high-density SNP mapping by estimating that too many SNPs (1 million) would be needed for a genomic scan than was practical. Fortunately, there were contradictory data available in gene identification programs in migraine and psoriasis that were entirely consistent with the APOE experiment and used SNP distances of 10-30 kB. [9] [10] [11] The basic assumption made by KruglyakFthat the world population is in equilibriumF was incorrect and introduced large errors in their estimates of the SNP density needed to find genes.
The near completion of the human genome sequencing projects and the development of a large, public SNP database during the period 1999-2001 provided the tools to be able to examine the utility of the whole genome SNP profiling for pharmacogenetics. 1 The use of this technology for AE pharmacogenetics has begun to be studied with medicines currently in the marketplace and will develop proof of principle experiments over the next 2-4 years. There has been widely held skepticism about regulatory authorities accepting SNP data in development dossiers. However, in April 2002, FDA officials published a call to sponsors of new drug applications to consult with the agency on the use of pharmacogenetics in clinical trials. 12 As a result, marketing sectors of the pharmaceutical industry were prompted to change their negative perceptions of the role of pharmacogenetics in drug development rather quickly. Regulators will now be able to review Phase II protocols with substudies that embed SNP profiling with the objective of being able to select patients with an SNP efficacy profile for Phase III trials. This can result in major savings in the drug development process by reducing the size and decreasing the time of Phase III studies. 13 In addition, the group of patients identified in Phase II as nonresponsive can now become the target population for developing other compounds in the company's pipeline. At present, identification of non-responders typically happens during postmarketing surveillance as a result of trial and error prescribing. In short, non-responders are characterized long after drug development studies when such information could be acted upon. Now, patient sub-populations with a lower chance of efficacy can be defined for immediate targeting for drug discovery. Future drug discovery strategies will demand that multiple lead molecules be developed in parallel to cover overlapping responding and non-responding populations that can be simultaneously identified in Phase II. Mass customization, based on safety and efficacy, will become the norm as it has in other industries, and will eventually be required by regulators. Medical care plans, insurance and government programs will want to pay only for effective medicines. Patients will receive fewer 'trial and error' medicines and the cost of effective treatment could decrease. Any rise in the cost of medicines will be because there are more effective treatments for unmet medical needs, rather than an increase in consumer advertising of attractive people running through fields of flowers or driving race cars.
DISEASE SUSCEPTIBILITY GENES
Companies are motivated to invest in science for practical business reasons, whether internally or in the nowpopular academic-government-industry consortia. One would have to be living in a cave without communications not to have heard that sequencing the human genome will provide a database containing all possible human targets to screen for therapeutic molecules. Journalists specialize in asking the tough questions, like 'When will the drug be available?' Academic investigators like to answer 'In the next 5-10 years if you support my research.' A huge market of buyers and sellers of targets has evolvedFbut we have to ask 'Where's the beef ?' Financial analysts demand a 15% larger stake from pharmaceutical companies every year.
The reality is that even if a diseasespecific gene target were screened tomorrow and a molecular hit was identified that interacted with that target next week, that molecule would need to be:
(1) developed into a lead compound, (2) optimized as a medicine, (3) tested in animals for toxicity, (4) tested in man for safety and efficacy, (5) reviewed by regulatory authorities, (6) manufactured and launched.
It would take no less than 7 years and probably 10-12 years before your neighborhood pharmacist filled the first prescription; ie, only if the molecule was actually related to the disease and could be selected efficiently. 14 From chemical lead to drug carries an attrition rate greater than 97%, and that does not include the failure of targets to produce viable hits or leads. Much of this attrition is because many targets are not relevant to human disease despite their selection based on popular, but incorrect, hypotheses. When the molecule is tested in humans, it does not always have the efficacy that is expected and required. Great strides will be made in reducing attrition by selecting screenable targets that are genetically validated (the gene and therefore the target are shown to be relevant to human disease). Unfortunately, the fruits of that development will not be consistently available for at least 10 years or more. Therefore, finding 'the beef' any time within this decade to meet economic expectations will be virtually impossible except with a few therapeutic proteins and rare drug development programs based on genetically related metabolic targets.
ADVERSE EVENT (AE) PHARMACO-GENETICS
Why would someone go out on a limb and state that AE pharmacogenetics will hit the marketplace within 1-4 years when it takes more than 10 years to develop a medicine? The reason is because pharmacogenetic research is well under way with medicines already in the marketplace. Increasing the use of a medicine based on an improved risk-to-benefit ratio is attractive to patients, physicians, regulators and pharmaceutical companies. Adverse events are a major cause of mortality and morbidity. 15, 16 Reducing that burden is both acceptable to society and good for business. Imagine the advantage of being able to document with comparative and accurate data that 'our drug is safer than yours,' especially with easy to measure SNP profiles.
These AE pharmacogenetics experiments are already in progress. Proof of principle experiments using candidate drugs have already yielded initial results. 17, 18 Whole genome screening experiments are under way with expected timelines for completing data collection and analysis by early 2003. It is therefore reasonable to expect that these AE experiments will be completed well before the disease gene target research impacts the medicine discovery process. Phase II and III clinical trials using whole genome SNP mapping technologies for efficacy pharmacogenetics now contemplated by regulators will begin to see results in 2-4 years.
A completed AE pharmacogenetic experiment involved abacavir, a GlaxoSmithKline marketed medicine for the treatment of HIV infection. Abacavir was selected because approximately 5% of patients have a hypersensitivity syndrome reaction (HSR) that can be life threatening if the drug is not stopped. 19 The HSR is distinctive and typically occurs within six weeks of treatment initiation. 20 The experiment is practical because both patients and treatment-matched controls are readily available for collecting DNA samples. The experiment was started in 1999, before the dream of a highdensity SNP map was a reality. As of 2001, HSR patients and matched HIVinfected control patients who also received abacavir treatment but did not experience the AE have been identified, informed, consented, and have contributed their DNA for use in this research.
Abacavir is a component of Trizivir s : a triple therapy HIV treatment designed to replace 10-20 pills a day with two tablets that cost less than the current treatment regimen. 21 A sensitive test for patients who are at risk for abacavir hypersensitivity, and therefore indicate who should not take the drug, would ultimately increase patient compliance by simplifying the tablet schedule and reducing the total drug bill.
Confirmed data from the initial candidate gene experiment have demonstrated that polymorphisms in two genes located in close proximity to each other are associated with HSR to abacavir. One of these, HLA-B57, is present in 5% of the population, but occurs in approximately 40-60% of the patients taking abacavir who experienced HSR. Similarly, the À238 polymorphism of TNF-alpha is present in approximately 7% of the population but it is found in about 45% of the HSR patients in the analysis. The gene loci for HLA-B57 and TNF-alpha are approximately 200 kB apart, not in strict LD, but certainly close enough to exhibit considerable overlap in the same set of HSR patients. Of 69 HLA-B57 positive patients, 65 also carried the TNF-alpha polymorphism, suggesting that the detection of AE-specific regions of SNPs need not be based solely on strictly defined blocks of LD. Whether this data set should be applied at the present time is now a matter of ongoing clinical debate by clinicians. More information on which to base clinical decisions is coming in early 2003 when it is expected that the whole genome SNP mapping will have been completed and an at-risk profile with considerably increased sensitivity defined. The practical concern at that time will be how fast a rapid and quick method of testing a relatively small number of informative SNPs (30-300) can be approved for clinical use. A false positive test in this case would simply indicate non-usage of abacavir and have no other diagnostic value. Patients will still need to be followed clinically for any signs of HSR, which would most likely become a rare AE. Clearly the application of these data would be a matter for close regulatory consultation. However, unlike the potential sensitivities with disease susceptibility genes, there are fewer ethical problems associated in being identified as not a suitable candidate for abacavir. As regulators become familiar with evaluating SNP mapping profiles for AE and for efficacy, AE prediction profiles linked to risk management programs will undoubtedly be considered. New protocols for large-scale drug surveillance could become part of a new paradigm for post-marketing surveillance. 22 Combined with efficacy profile selection embedded within clinical trials, the benefit-risk ratios for drugs will increase significantly. By the next decade, such data may be required, especially in cases in which efficacy is limited to a small proportion of the patient population, or for orphan diseases.
PHARMACEUTICAL COMPANIES ANTICIPATED WHOLE GENOME APPLICATIONS OF PHARMACO-GENETICS
In 1998 there were multiple biotechnology companies who were seeking to corral their own sets of patented SNPs, a factor that would have complicated and delayed creating an efficient and complete dense SNP map. Ten pharmaceutical companies and the Wellcome Trust created The SNP Consortium (TSC) for the purpose of identifying and placing into the public domain 300,000 SNPs with 150,000 of the SNPs mapped onto the human genome. 23 The rationale was that the regulatory authorities would only recognize an industry-standard SNP map for profiling patients for pharmacogenetic analyses, rather than many different proprietary maps. By most accounts, TSC was a resounding success for a new industry-public collaboration.
The sequencing was completed within two years and more than 2 million mapped SNPs are now in the public domain. 1 The next obvious step would be to create linkage disequilibrium maps for multiple ethnic groups. 24 While that activity is being considered as an extension of TSC beyond the time of its planned demise, an ordered SNP map of more than 200,000 SNPs was being constructed. By December 2001, more than 200,000 SNP assays had been tested and validated. The second genome scan phase of the abacavir experiment was initiated in January 2002. This particular map of polymorphisms will certainly not become the industry standard, but the experimental variables of 'how many, how close and how fast' inherent in high-throughput SNP mapping experiments can be explored during this year. Whole genome adverse event SNP profile results for abacavir should be available in early 2003. When linkage disequilibrium maps are constructed and tested over the next few years, the number of SNPs required for pharmacogenetic SNP profiling will no doubt decrease as successive drafts of industry-standard maps are developed.
EFFICACY PHARMACOGENETICS
The use of SNP mapping profiles to predict whether an individual will respond appropriately to a medicine is much more complicated than analyzing for AE pharmacogeneticsF both scientifically and economically. 25 AEs are comparatively easy to diagnose accurately. Pharmacogeneticbased efficacy would be measured in relatively large Phase II clinical trials. Such trials will need well-defined efficacy end points. The goal would be to select patients for Phase III clinical trials in whom efficacy can be predicted by a pharmacogenetic profile. 26 Phase III trials could then be smaller and faster, but would require the determination of a pharmacogenetic efficacy selection profile that eventually would be a basis for making prescribing decisions. 27 A new patient subgroupFthose in whom efficacy of the first molecule would not be predicted by the profileFcould also be identified as a target population for additional drug discovery in real time.
There are many additional variables that may affect efficacy pharmacogenetics that are not a factor for AEs. The placebo effect could impact the deduced pharmacogenetic efficacy profiles, having an effect akin to a pseudogene. The usefulness of efficacy pharmacogenetics would be minimal when the proportion of the responding population is large, but would be maximized when a clearly responding proportion of patients is small. There are other variables as well. Efficacy pharmacogenetics is currently the subject of risk-adjusted economic valuations and will no doubt be less of a general factor in drug development than many have speculated.
A potential regulatory concern involves the safety of patients who do not have the genetic profile for efficacy to qualify for the drug, but who want to try it based on a small chance that it may be effective for them. 28 The concern is that if adverse events are noted during post-marketing surveillance, then the AE SNP profile will reflect only treated patients. In fact, untreated patients will also have had their DNA tested to determine the efficacy SNP profile and this DNA sample could be saved for comparing the AE SNP profile in treated vs untreated patients. It remains to be determined whether the AE profile would be different in patients who do not share the efficacy profile, but there is no reason to suspect that the AE profile would have a different population frequency (Figure 1 ). The SNP regions defining profiles for efficacy and those for susceptibility for AEs would be expected to be inherited at independent loci. This could certainly be tested in real situations in order to develop data based guidance for regulatory purposes.
SNP MEASUREMENT TECHNOLOGIES
Imagine a ruler that is 15,000 ft long with an informative SNP every inch.
Screening for a series of SNPs or SNP Print SM means finding phenotype (either AEs or efficacy) association signals from two or more consecutive or nearby SNPs to detect a region of linkage disequilibrium (LD). 25 , 29 The SNP Print SM would identify multiple, very specific LD locations along the ruler that define the AE or efficacy profile. Following the initial screen, additional SNPs from each location could be added and mapped to confirm and increase the statistical significance of each peak. Thus, along a linear scale, specific combinations of LD locations can profile and predict a phenotype (just as with disease loci) (Figure 2 ).
High-throughput SNP analysis was an expensive reality in 2001, with technology companies vying for faster, more efficient, more accurate and less expensive methods. As occurred in the DNA sequencing field, the cost of SNP assays continues to decrease with time. For SNP comparisons among phenotypes, for example, those treated patients with an AE and those treated patients without an AE, initial screens could be performed in mixing experiments. By mixing the DNA of 100 individuals into one tube, the allele frequency ratio at each point can be compared for detection of robust association differences. Interesting regions can then be confirmed with additional Figure 1 It has not been determined whether the genetic adverse event profile would be different in those patients who are not treated and do not share the efficacy profile of treated patients. However, there is no reason to suspect that the AE profile would have a different population frequency.
markers as a second step to defining a Medicine Response Test. The cost could be decreased by two orders of magnitude and protocols allowing sample mixing could be selected for methods of analysis. The second step involving the examination of fewer SNPs might be performed on each individual DNA sample by a more individually accurate process.
Once the pattern of peaks associated with the phenotype is recognized and confirmed, only those SNPs that define the peaks need to be tested using simpler, more affordable point-ofservice technologies. One can easily envision a microarray or a 384-well plate kit containing the primers for testing the SNPs associated with increased risk for an AE, available at central laboratories for an overnight test before the prescription is filled. It is also conceivable that a desktop kit using a prepared assay on 384-or 1536-well plates might be available for automated analyses at the point of patient care.
Disease Gene Hunting
Most of the attention in academic commentaries and in biotechnical literature has focused on identifying new disease susceptibility genes by linkage and/or association methods. 4 The use of SNP methods and SNP maps will rapidly accelerate the identification of disease variant associations in sets of genes throughout the genome. However, these studies will only be possible when a major shift back to clinical research support replaces the pervading over-emphasis on technology. To perform linkage studies, families must be identified, consented, examined, and have contributed DNA samples. Whether one uses current dinucleotide repeat maps or SNP linkage maps, collecting enough high-quality clinical information and banked DNA is not a high-throughput technology. As with all other sciences, if one does not have the proper substrates to study (in this case DNA from patients and controls), it does not really matter whether there is a fantastic new technology that can be applied. Besides the cost and difficulty of collecting test and confirmation family sets, as well as 'sporadic' patient populations and controls for further conformation in the general population, linkage studies currently use an expensive and archaic technology. Most studies use 400-500 dinucleotide repeat markers spread over the genome at 10 cM intervals (approximately 10 million base pairs depending on where the markers are in the genome) in a labor-intensive, expensive gel-based or sequencing methodology. The benefit of the dinucleotide repeats is that they can increase the useful information at each point on the genome because each may have many repeat variants in the population. Thus each dinucleotide repeat analysis provides more information compared with the analysis of the two variants of restriction fragment length polymorphisms (RFLPs)Fthe old gel-based technology term for what are now known as SNPs. What has changed over the past two years is that many more SNPs can be measured faster and less expensively with new high-throughput systems. What has been missing is a SNP map designed for performing linkage analyses.
The SNP Consortium is currently sponsoring the development of a linkage SNP map that is scheduled to be completed and in the public domain by mid-2002. Two biotechnical companies have been commissioned by TSC to create the map and the reagents to use the map. Once completed, there will be a 5 cM map (twice as dense as dinucleotide repeat maps) with approximately 3500 SNPs readily available to small laboratories. A linkage study that would take months with current technology could be screened in one day using, for example, 384-well plates (3500 SNPs Â 2 alleles per SNP Â 20 plates)Fif the DNA from well-documented families were available. As an example, in 2001 it took GSK Screening Centers at Duke University Medical Center and the University of Western Australia approximately eight months to run current linkage markers through a large number of asthma families. In 2002, the same study should take a week or twoFand because it can be performed in an automated, high-throughput environment, the total cost would be reduced by an order of magnitude. The SNP Linkage Map will be a boon, especially to small laboratories, since they will no longer need to be dependent on large laboratory facilities, with Figure 2 Genetic markers in the HLA-B region that are associated with hypersensitivity to abacavir. The À238 TNF-alpha and the HLA-B57 polymorphisms were both found to be associated with susceptibility to hypersensitivity to abacavir. These markers were found to be in close proximity to each other on the same chromosome. Several other intervening markers had varying degrees of positive association. The À238 TNF-alpha and the HLA-B57 polymorphisms are not within the same linkage disequilibrium (LD) blocks but show by overlapping patient sets that detection for pharmacogenetics can exceed the LD blocks, which indicates that fewer than 200,000 single nucleotide polymorphisms (SNPs) will be necessary to define SNP profiles.
long waits for their grant applications to be approved, and huge costs to perform the linkage analyses with their families. The shift in linkage science will go from a few large laboratories back to the clinical researcher. GSK is establishing four additional academic centers worldwide with excess capacity for SNP analyses beyond our own experimental studies, so that direct academic collaborations can be formed among our academic partners for inexpensive and rapid SNP linkage studies with no industry strings attached. For commercial and regulatory studies, Good Laboratory Practice (GLP) laboratories will no doubt be developed.
Association Studies
Once linkage regions of the genome have been mapped, the central problem remains of how to find the polymorphisms of the susceptibility genes associated with the disease. The regions are often quite large and susceptibility genes have fuzzy boundaries, primarily because it is not possible to ascertain who will develop disease with any certainty later in life in late-onset families. Candidate genes within the region can sometimes be inferred from the genome-wide databases that are currently available. Unfortunately most of the few validated association genes were not obvious candidates.
Constructing a 4 Mb map around APOE in 1997 took approximately 20 scientists about four months to create using both BAC and YAC mapping techniques. 5 It took another six months to analyze several hundred SNPs in hundreds of Alzheimer disease patients and controls. 6, 7 The conclusion was that if these methods had been available in 1988, APOE could have been identified in less than a year after the original linkage was found. In 2002 there is a whole genome map for pharmacogenetics available, courtesy of TSC. If a linkage region were found for any disease, the SNP map already exists, as do the tools to measure a few hundred SNPs in a few hundred patients and controls. The study would take a couple of weeks, most of which would be aliquoting the DNA samples onto plates, etc. If patient plates were prepared now, then the study would take a day or two after the linkage regions are completed. Thus linkage regions can be identified more rapidly, and there will also be quick gene association tools based on SNPs. Real progress will not be automatic, since the clinical research to inform and examine patients, and collect sufficient DNA resources will be the remaining bottleneck. Do we really want to expend the resource to sequence another species quickly, or should we divert major financial support from technological repetition (such as sequencing every organism) back to the human clinical research that will be necessary for defining the genetic components of disease? So Where's the Beef? Finding the susceptibility gene polymorphisms that underline the expression of human diseases is not the only appropriate end point to consider in 2002. 4 Using this knowledge to improve the attrition rate of drug discovery is a more practical goal. The transition from academic knowledge to medicines will need to be based on tractable targets, ie, those that can be screened, not just identified diseaseassociated variants of genes. The general public wants safer, more effective, and affordable treatments for huge unmet medical needs. If new treatments or preventative therapies are the 'beef,' then look to the pharmaceutical industry's R&D for the development of pharmacogenetics when you ask, 'Where's the beef ?' Even the latest tools to slice the beef were provided largely through a focused partnership of the pharmaceutical industry with the Wellcome Trust, a British charity, in supporting academic sequencing laboratories to find SNPs. New models of academic-industry relationships compatible with academic projects and utilizing such highthroughput screening laboratories on up-to-date equipment will accelerate the application of pharmacogenetics as well as the next wave of diseaserelevant drug discovery. 
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